Clinical Trial Update: A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib

View source ↗

Summary

This clinical trial update reports a real-world study evaluating the effectiveness and safety of ribociclib or alpelisib in HR+/HER2- breast cancer. It is liste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)
• Piqray (alpelisib)

Snippet

Sponsor: Novartis | Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer | Status: COMPLETED